Five Analysts Upgrade Niagen's Rating Consistently

Summary

Niagen Bioscience, Inc. (NASDAQ: NAGE) has received a consensus ‘buy’ recommendation from five analysts with an average target price of $13.22. Recent upgrades include Wall Street Zen raising its rating to ‘strong buy’, and Roth Capital increasing its target price to $23.00. The stock is currently trading at $11.26, reflecting a 0.4% decrease, with a market cap of $886.95 million. Institutional investors hold 15.41% of the stock, indicating growing interest in the company’s focus on NAD+ research and commercialization.Market Beat

Impact Analysis

This event is classified at the company level as it specifically pertains to Niagen Bioscience, Inc. The upgrades by analysts and the increased target price suggest positive market sentiment and potential upside in the stock price. First-order effects include the potential for increased investor interest and stock price appreciation as analysts’ recommendations often influence market perceptions. Second-order effects might include enhanced visibility within the biotech sector, potentially attracting further institutional investment. Investors may consider this an opportunity to invest in a company with a promising trajectory in the NAD+ research space. However, they should also be aware of risks such as market volatility and execution challenges in the commercialization of their research.Market Beat+ 3